Deletions of the 3'BCR and 5'ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells

Mickaël Fournier; Stéphanie Lacrosse; Mauricette Jamar; Vincent Bours; Christian Herens

doi:10.1016/j.cancergencyto.2005.01.002

Deletions of the 3'BCR and 5'ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells

Cancer Genet Cytogenet. 2005 Jul 15;160(2):184-7. doi: 10.1016/j.cancergencyto.2005.01.002.

Authors

Mickaël Fournier¹, Stéphanie Lacrosse, Mauricette Jamar, Vincent Bours, Christian Herens

Affiliation

¹ Center for Human Genetics, University of Liège, CHU, Tour de Pathologie, B23, Sart Tilman, 4000 Liège, Belgium.

PMID: 15993277
DOI: 10.1016/j.cancergencyto.2005.01.002

Abstract

Deletions of the 5'ABL region adjacent to the t(9;22)(q34;q11) have recently been reported in 8-32.7% of patients with chronic myeloid leukemia (CML). The deletions were visualized with fluorescence in situ hybridization using, in the majority of the cases, the Vysis LSI BCR/ABL ES (extra signal) probe. In our series, 10 of 99 CML patients (10.1%) were characterized by a 5'ABL deletion. We show that 3'BCR losses are observed in nearly all the cases with 5'ABL deletions. Moreover, the different genetic events (Philadelphia chromosome formation; 5'ABL and 3'BCR deletions) occur simultaneously in a one-step process without any evidence for genetic instability in the target bone marrow cells.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Female
Fusion Proteins, bcr-abl / genetics*
Genomic Instability / genetics*
Humans
In Situ Hybridization, Fluorescence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Male
Middle Aged
Sequence Deletion / genetics*

Substances

Fusion Proteins, bcr-abl